Spravato and IV ketamine are often discussed as if they’re interchangeable. They aren’t — and the differences matter a lot when you’re choosing between them.
What You’ll Learn
- The actual molecular difference and why it changes the experience
- FDA status and how that drives insurance coverage
- Cost differences (the gap is enormous)
- Which conditions each is realistically used for
- How to choose between them based on your situation
Same Family, Different Molecule
Ketamine the racemic drug is a 50/50 mixture of two mirror-image versions of the same molecule: S-ketamine (also called esketamine) and R-ketamine. Spravato is the S-isomer alone, purified.
That isn’t a marketing distinction. The S-isomer binds the NMDA glutamate receptor roughly 3-4x more tightly than the R-isomer, which means:
- Lower mg-equivalent dose for similar receptor occupancy
- Slightly different subjective experience — Spravato users often report less of the “dissociative trip” quality some patients seek with IV ketamine
- Different elimination kinetics because the body metabolizes the two isomers at different rates
Some researchers think the R-isomer actually contributes to ketamine’s longer-tail antidepressant effect via different mechanisms (BDNF signaling, mTOR pathway). That’s still being argued in the literature.
The FDA Status Gap
This is the practical headline:
- Spravato (esketamine) is FDA-approved for treatment-resistant depression (2019) and major depressive disorder with active suicidal ideation (2020). Sold by Janssen, distributed under a strict REMS program.
- IV ketamine for depression is off-label. Ketamine itself is FDA-approved as an anesthetic from 1970, but its use for depression, PTSD, anxiety, and chronic pain is all clinical practice rather than approved indication.
That distinction drives almost everything downstream — insurance, cost, who can prescribe, where you can get it, and what your visit looks like.
Route, Setting, and What a Session Feels Like
| Spravato | IV Ketamine | |
|---|---|---|
| Route | Nasal spray (self-administered) | IV infusion (most common); also IM, sublingual |
| Dose | 56 or 84 mg per session | 0.5 mg/kg over 40 min (typical antidepressant dose) |
| Where | REMS-certified clinic only | Any ketamine clinic |
| Monitoring | 2 hr in-clinic observation | Typically during infusion + brief recovery |
| Driving | Not allowed for 24 hrs | Not allowed same day |
| Co-medication | Must be taken with an oral antidepressant | Often standalone |
| Schedule | Twice weekly × 4 wks (induction), then weekly/biweekly | 6 infusions over 2-3 wks, then boosters as needed |
Most patients describe the Spravato experience as “floaty, dreamy, slightly dissociative” — milder than a full IV ketamine session. IV ketamine at antidepressant doses produces stronger dissociation in most patients, which some experience as therapeutic and others find uncomfortable.
Cost — This Is Where the Gap Is Biggest
Spravato (with insurance): Most insured patients pay $10-$75 per session in copays. Without insurance, retail is $590-$885 per dose.
IV Ketamine (typically cash-pay): $400-$800 per infusion in the U.S. A standard 6-infusion induction course runs $2,400-$4,800. Maintenance boosters add up — many patients need one every 3-6 weeks.
Over a year of treatment, the difference can easily be $10,000+ depending on your insurance and ketamine clinic pricing.
Indications and Off-Label Use Cases
Spravato is approved for:
- Treatment-resistant depression (TRD) — adults who’ve failed 2+ antidepressants in the current episode
- Major depressive disorder with active suicidal ideation
IV ketamine is used off-label for:
- Treatment-resistant depression (most common use)
- Acute suicidal ideation
- PTSD (growing evidence base)
- Severe anxiety disorders
- OCD
- Chronic pain conditions (CRPS, fibromyalgia, neuropathic pain)
- Treatment-resistant bipolar depression
If your diagnosis is TRD with adequate prior medication trials, both options are on the table. If you’re seeking treatment for PTSD, anxiety, or pain, IV ketamine is your only realistic ketamine-family option — Spravato isn’t approved for those.
Side Effects
The side-effect profiles overlap substantially. Both can cause:
- Dissociation (feeling detached from body or surroundings)
- Sedation
- Blood pressure spikes during/after dosing
- Nausea
- Vertigo or dizziness
- Headache
Specific to Spravato: Nasal discomfort, altered taste, hypoesthesia (numbness in mouth/throat). The REMS program exists partly to monitor for the BP spike, which can be more pronounced with esketamine in some patients.
Specific to IV ketamine: Higher rates of “emergence” experiences (vivid dreams or hallucinations during/after the infusion). Slightly higher abuse potential because of the more pronounced dissociation.
Durability of Response
Both produce rapid antidepressant effects — improvement often within hours to 1-3 days of the first session. Without maintenance, response typically fades within 1-3 weeks. That’s why both treatments use ongoing maintenance schedules:
- Spravato: Weekly or biweekly maintenance dosing, typically indefinitely as long as it’s working.
- IV ketamine: Booster infusions at varying intervals (3 weeks to 3 months), individualized.
Patients sometimes use TMS or other treatments in parallel to extend response and reduce maintenance frequency.
Who Should Choose Which?
Spravato is usually the right starting point if:
- You have insurance that covers it
- Your diagnosis is TRD or MDD with suicidal ideation
- You want a more standardized dose and protocol
- The 2-hour clinic time twice a week fits your schedule
IV ketamine is usually the right path if:
- You’re being treated for PTSD, anxiety, OCD, or chronic pain (Spravato isn’t approved)
- You haven’t tried 2+ antidepressants yet (Spravato requires this)
- You can absorb cash-pay costs
- You want more flexibility in dose, schedule, and adjunctive psychotherapy integration (some clinics pair ketamine with psychotherapy in the same session)
The Honest Take
For most insured U.S. patients with treatment-resistant depression, Spravato is the more accessible and economically viable option. For patients with PTSD, anxiety, or chronic pain — or those without insurance — IV ketamine remains the more flexible tool.
What both share: rapid onset, real efficacy, and the need for ongoing maintenance. Neither is a one-and-done cure for chronic mood disorders. Both work best as part of a broader treatment plan that includes therapy, lifestyle stability, and often other medications or neuromodulation.
If you’re trying to choose, the right starting point is a psychiatrist who has clinical experience with both — not a clinic that only offers one.